Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 11/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.58 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.54 |
| ▸ | CDK9 | P50750 | 2/20 | 0.54 |
| ▸ | CDK7 | P50613 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.50 |
| ▸ | CDK4 | P11802 | 4/20 | 0.48 |
| ▸ | IKBKB | O14920 | 4/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DKK1 | O94907 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27684108 | 0.91 | CDK2 (0.54) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL2085458 | 0.90 | CDK2 (0.55) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL2085989 | 0.86 | IKBKB (0.60) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL4166880 | 0.84 | CDK2 (0.66) | CDK2CDK9CDK7CDK4GSK3B | |
| SCHEMBL2083985 | 0.84 | CDK2 (0.69) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL4157071 | 0.83 | CDK2 (0.59) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL4160005 | 0.83 | CDK2 (0.61) | CDK2CCNT1CDK9CDK7CDK4 | |
| SCHEMBL27664540 | 0.82 | CDK2 (0.51) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL2086822 | 0.81 | CDK2 (0.59) | CDK2CLK1CCNT1CDK9CDK7 | |
| SCHEMBL4158693 | 0.80 | CDK2 (0.65) | CDK2CCNT1CDK9CDK7CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | claimed |
| EP-1951307-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | Cyclacel Limited (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | claimed |
| JP-2007509117-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | claimed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | claimed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | claimed |
| EP-1678171-B1 | 2-AMINO-4-THIAZOLONE-PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | CYCLACEL LTD (GB) | 2016-09-14 | — | — | EP | disclosed |
| US-7902361-B2 | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| EP-1951307-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | Cyclacel Limited (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054725-A2 | COMBINATION OF A CDK-INHIBITOR AND A HDAC-INHIBITOR | CYCLACEL LIMITED (GB) | 2007-05-18 | — | — | WO | disclosed |
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | CYCLACEL LIMITED (GB) | 2007-01-25 | — | — | US | disclosed |
| CN-1898237-A | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | CYCLACEL LTD (GB) | 2007-01-17 | — | — | CN | disclosed |
| EP-1678171-A1 | PYRIMIDIN-4-YL-3,4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | Cyclacel Limited (GB) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042525-A1 | PYRIMIDIN-4-YL-3, 4-THIONE COMPOUNDS AND THEIR USE IN THERAPY | CYCLACEL LIMITED (GB) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021452-A1 | Pyrimidin-4-YL-3, 4-thione compounds and their use in therapy | MSRB3, DHFR, CBR3 | CDK2 459/4885CLK1 2868/4885CCNT1 490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.